Protein Kinase C-Mediated Regulation of Matrix Metalloproteinase and Tissue Inhibitor of Metalloproteinase Production in a Human Retinal Müller Cells

REFERENCES

• Garner A. Histopathology of diabetic retinopathy in man. Eye (Lond) 1993;7 (Pt 2):250–253.
   Google Scholar
• Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97:512–523.
   PubMed Web of Science ®Google Scholar
• Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005;85:597–607.
   PubMed Web of Science ®Google Scholar
• Navaratna D, McGuire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007;56:2380–2387.
   PubMed Web of Science ®Google Scholar
• Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48–58.
   PubMed Web of Science ®Google Scholar
• Nagase H. (1986). Zinc Metalloproteinases in Health and Disease. London: Taylor and Francis.
   Google Scholar
• Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863–868.
   PubMed Web of Science ®Google Scholar
• Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999;107:111–119.
   PubMed Web of Science ®Google Scholar
• De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998; 39: 1256–1260.
   Google Scholar
• Kosano H, Okano T, Katsura Y et al. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 1999;64:2307–2315.
   PubMed Web of Science ®Google Scholar
• Noda K, Ishida S, Inoue M et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2003;44:2163–2170.
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Eriqat C et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809–813.
   PubMed Web of Science ®Google Scholar
• Salzmann J, Limb GA, Khaw PT et al. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 2000;84:1091–1096.
   Google Scholar
• Grant MB, Caballero S, Tarnuzzer RW et al. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 1998;47:1311–1317.
   Google Scholar
• Tout S, Chan-Ling T, Holländer H, Stone J. The role of Müller cells in the formation of the blood-retinal barrier. Neuroscience 1993;55:291–301.
   PubMed Web of Science ®Google Scholar
• Newman E, Reichenbach A. The Müller cell: a functional element of the retina. Trends Neurosci 1996;19:307–312.
   PubMed Web of Science ®Google Scholar
• Limb GA, Daniels JT, Pleass R, Charteris DG, Luthert PJ, Khaw PT. Differential expression of matrix metalloproteinases 2 and 9 by glial Müller cells: response to soluble and extracellular matrix-bound tumor necrosis factor-alpha. Am J Pathol 2002;160:1847–1855.
   Google Scholar
• Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002;47 Suppl 2:S263–S269.
   PubMed Web of Science ®Google Scholar
• Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004;20:28–43.
   PubMed Web of Science ®Google Scholar
• Alexander JP, Bradley JM, Gabourel JD, Acott TS. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1990;31:2520–2528.
   PubMed Web of Science ®Google Scholar
• Padgett LC, Lui GM, Werb Z, LaVail MM. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation. Exp Eye Res 1997;64:927–938.
   PubMedGoogle Scholar
• el-Shabrawi Y, Eckhardt M, Berghold A et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye (Lond) 2000;14 (Pt 3A):375–383.
   Google Scholar
• Irschick EU, Haas G, Troger J, Ueberall F, Huemer HP. Involvement of protein kinase C in phagocytosis of human retinal pigment epithelial cells and induction of matrix metalloproteinase secretion. Int Ophthalmol 2009;29:333–341.
   Google Scholar
• Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT. In vitro characterization of a spontaneously immortalized human Müller cell line (MIO-M1). Invest Ophthalmol Vis Sci 2002;43:864–869.
   PubMed Web of Science ®Google Scholar
• Trompezinski S, Pernet I, Schmitt D, Viac J. UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res 2001;50:422–427.
   PubMedGoogle Scholar
• Sato T, Koike L, Miyata Y et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res 2002;62:1025–1029.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Sato T, Yano M, Ito A. Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase ½ phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin. Mol Cancer Ther 2004;3:839–847.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Sato T, Imada K, Dobashi A, Yano M, Ito A. A citrus polymethoxyflavonoid, nobiletin, is a novel MEK inhibitor that exhibits antitumor metastasis in human fibrosarcoma HT-1080 cells. Biochem Biophys Res Commun 2008;366:168–173.
   PubMed Web of Science ®Google Scholar
• Crawford HC, Matrisian LM. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996;49:20–37.
   PubMedGoogle Scholar
• Mueller MS, Mauch S, Sedlacek R. Structure of the human MMP-19 gene. Gene 2000;252:27–37.
   PubMedGoogle Scholar
• Lohi J, Lehti K, Valtanen H, Parks WC, Keski-Oja J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000;242:75–86.
   Web of Science ®Google Scholar
• Illman SA, Keski-Oja J, Lohi J. Promoter characterization of the human and mouse epilysin (MMP-28) genes. Gene 2001;275:185–194.
   PubMed Web of Science ®Google Scholar
• Marchenko GN, Marchenko ND, Leng J, Strongin AY. Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J 2002;363:253–262.
   PubMed Web of Science ®Google Scholar
• Marchenko GN, Marchenko ND, Strongin AY. The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J 2003;372:503–515.
   Google Scholar
• Baramova E, Foidart JM. Matrix metalloproteinase family. Cell Biol Int 1995;19:239–242.
   PubMed Web of Science ®Google Scholar
• Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997;15:180–189.
   PubMed Web of Science ®Google Scholar
• De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998; 39: 1256–1260.
   Google Scholar
• Salzmann J, Limb GA, Khaw PT, Gregor ZJ, Webster L, Chignell AH, Charteris DG. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 2000; 84: 1091–1096.
   Google Scholar
• Descamps FJ, Martens E, Kangave D et al. The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res 2006;83:401–407.
   Google Scholar
• Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 1991;47:230–235.
   PubMed Web of Science ®Google Scholar
• Anand-Apte B, Bao L, Smith R et al. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 1996;74:853–862.
   Web of Science ®Google Scholar
• Anand-Apte B, Pepper MS, Voest E et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997;38:817–823.
   PubMed Web of Science ®Google Scholar
• Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351–358.
   PubMed Web of Science ®Google Scholar
• Bertaux B, Hornebeck W, Eisen AZ, Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991;97:679–685.
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29–32.
   PubMed Web of Science ®Google Scholar
• Yamada E, Tobe T, Yamada H et al. TIMP-1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol 2001;16:87–97.
   PubMed Web of Science ®Google Scholar